BioVaxys Technology Corp.

Research BioVaxys Technology Corp. (5LB0) on Bullrun: market cap EUR 1.18M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Ticker5LB0
ExchangeF
CountryCanada
SectorHealthcare
IndustryBiotechnology
CurrencyEUR
Market capEUR 1.18M
Financial periodQ2 2025
RevenueCAD 0
Net income-CAD 1.32M
Free cash flow-CAD 1.06M

Valuation Snapshot

latest market cap is EUR 1.18M.

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-08-18	EUR 1.18M	n/a	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About BioVaxys Technology Corp.

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases.

Related stock research

Canada stocks Canada Healthcare stocks A-Z stock index

Other Healthcare stocks

Entheon Biomedical Corp. (1XU) NANOSPHERE HEA.SCIENCES (2CG) MedMira Inc (47M) BRAXIA SCIENTIFIC CORP. (4960) WAVERLEY PHARMA INC. (5GZ) GLOW LIFETECH CORP. (9DO) NERVGEN PHARMA CORP. (9UA) AbCellera Biologics Inc (ABCL) Appili Therapeutics Inc (APLI) Arch Biopartners Inc (ARCH) Aurinia Pharmaceuticals Inc (AUPH) Briacell Therapeutics Corp (BCT)

Frequently asked questions

What is BioVaxys Technology Corp.'s market cap?

BioVaxys Technology Corp.'s market capitalization is EUR 1.18M.